MiNK Therapeutics Reports Q3 2024 Equity Changes, Agenus Agreement
Ticker: INKT · Form: 10-Q · Filed: Nov 14, 2024 · CIK: 1840229
Sentiment: neutral
Topics: intercompany-agreement, equity-changes, financial-reporting, biotech
Related Tickers: AGEN
TL;DR
MiNK's Q3 2024 10-Q shows equity shifts & a new service deal with Agenus.
AI Summary
MiNK Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported changes in its equity accounts, including an increase in Additional Paid-In Capital and Common Stock. Notably, the filing mentions a "New Intercompany Service Agreement" with Agenus Inc. and details business services and occupancy costs related to Agenus Inc. for the nine months ended September 30, 2024.
Why It Matters
This filing provides insight into MiNK Therapeutics' financial structure and its ongoing relationship with Agenus Inc., which could impact future operations and collaborations.
Risk Assessment
Risk Level: medium — The company's financial health and operational dependencies, particularly its relationship with Agenus Inc., present medium-term risks.
Key Numbers
- 2024-09-30 — Reporting Period End (Covers the third quarter of fiscal year 2024.)
- 2024-01-01 to 2024-09-30 — Nine Months Ended (Period for which financial data is reported, including service costs.)
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Filer
- 2024-09-30 (date) — Reporting period end date
- Agenus Inc. (company) — Related company in service agreement
- New Intercompany Service Agreement (contract) — Key agreement mentioned
FAQ
What is the nature of the "New Intercompany Service Agreement" with Agenus Inc.?
The filing mentions a "New Intercompany Service Agreement" with Agenus Inc. for the period of January 1, 2024, to September 30, 2024, and details related business services and occupancy costs, but does not specify the exact terms or services.
How did MiNK Therapeutics' equity change during the nine months ended September 30, 2024?
The filing indicates changes in equity accounts, including increases in 'Additional Paid-In Capital' and 'Common Stock' during the nine months ended September 30, 2024.
What were the business services and occupancy costs related to Agenus Inc. for the nine months ended September 30, 2024?
The filing lists 'Business Services and Occupancy Costs' related to Agenus Inc. for the nine months ended September 30, 2024, but the specific dollar amount is not provided in the excerpt.
What was MiNK Therapeutics' former company name?
MiNK Therapeutics, Inc.'s former company name was AgenTus Therapeutics, Inc., with a name change date of January 12, 2021.
What is MiNK Therapeutics' primary business classification?
MiNK Therapeutics, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with the SIC code [2836].
Filing Stats: 4,433 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-11-14 16:05:25
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT Nasdaq Capital Marke
Filing Documents
- inkt-20240930.htm (10-Q) — 1192KB
- inkt-ex31_1.htm (EX-31.1) — 15KB
- inkt-ex31_2.htm (EX-31.2) — 15KB
- inkt-ex32_1.htm (EX-32.1) — 10KB
- 0000950170-24-127033.txt ( ) — 4544KB
- inkt-20240930.xsd (EX-101.SCH) — 756KB
- inkt-20240930_htm.xml (XML) — 524KB
Financial Statements (Unaudited)
Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Deficit for the three and nine months ended September 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 5 Notes to Unaudited Interim Condensed Consolidated Financial Statements 6 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 19 Item 4.
Controls and Procedures
Controls and Procedures 19 PART II. OTHER INFORMATION 20 Item 1.
Legal Proceedings
Legal Proceedings 20 Item 1A.
Risk Factors
Risk Factors 20 Item 5. Other Information 20 Item 6. Exhibits 21
—FINANCI AL INFORMATION
PART I—FINANCI AL INFORMATION
Financi al Statements
Item 1. Financi al Statements. MINK THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDAT ED BALANCE SHEETS (Unaudited) September 30, 2024 December 31, 2023 ASSETS Cash and cash equivalents $ 6,328,239 $ 3,367,229 Prepaid expenses 235,786 53,111 Other current assets 11,195 177,964 Total current assets 6,575,220 3,598,304 Equipment, net of accumulated depreciation of $ 476,741 and $ 495,638 at September 30, 2024 and December 31, 2023, respectively 799,522 953,977 Total assets $ 7,374,742 $ 4,552,281 LIABILITIES AND STOCKHOLDERS' DEFICIT Accounts payable $ 2,361,175 $ 3,911,973 Accrued liabilities 2,645,494 5,037,361 Other current liabilities 2,392,324 2,453,251 Total current liabilities 7,398,993 11,402,585 Related party note 4,611,644 — Other long-term liabilities 2,942 48,072 Due to related parties 12,915,252 11,157,073 Commitments and contingencies STOCKHOLDERS' DEFICIT Common stock, par value $ 0.00001 per share; 150,000,000 shares authorized; 39,549,975 and 34,599,119 shares issued at September 30, 2024 and December 31, 2023, respectively 395 346 Additional paid-in capital 124,836,985 115,772,085 Accumulated other comprehensive loss ( 672,838 ) ( 430,947 ) Accumulated deficit ( 141,718,631 ) ( 133,396,933 ) Total stockholders' deficit ( 17,554,089 ) ( 18,055,449 ) Total liabilities and stockholders' deficit $ 7,374,742 $ 4,552,281 See accompanying notes to unaudited condensed consolidated financial statements. 1 MINK THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 540,638 $ 3,427,373 $ 4,929,993 $ 12,179,365 General and administrative 1,163,033 1,796,188